糖尿病新世界
糖尿病新世界
당뇨병신세계
Diabetes New World
2015年
18期
93-96
,共4页
糖尿病肾病%贝那普利%厄贝沙坦%疗效
糖尿病腎病%貝那普利%阨貝沙坦%療效
당뇨병신병%패나보리%액패사탄%료효
Benner Pury%Diabetic nephropathy%Irbesartan%Curative effect
目的 探讨贝那普利联合厄贝沙坦治疗糖尿病肾病的临床疗效. 方法 选取2014年1月—2015年6月来该院入住的糖尿病肾病患者186例,随机分为对照组和观察组,两组成员均为93例.给予对照组单一贝那普利,给予观察组贝那普利联合厄贝沙坦. 检测尿微量白蛋白排泄率(UAER)、血尿素氮(BUN)、血肌酐(Scr)、收缩压(SBP)、舒张压(DBP)的变化,作为根据诊断标准,判定患者的有效率.结果 对照组和观察组的UAER、SBP、DBP均降低,且观察组降低的更加明显.治疗后比较,P<0.05,差异有统计学意义.BUN、Scr治疗前后比较,P>0.05,差异无统计学意义.观察组的不良反应较对照组少.对照组的总有效率为69.89%,观察组的总有效率为90.32%,两组数据相比,观察组的有效率明显优于对照组,统计学处理后差异有统计学意义(χ2=10.58,P<0.05). 结论 贝那普利联合厄贝沙坦治疗糖尿病肾病时,能够控制血糖和血压、降低蛋白尿的排出量,具有较好的治疗疗效,减少不良反应,改善了患者的生活质量. 因此值得广泛应用.
目的 探討貝那普利聯閤阨貝沙坦治療糖尿病腎病的臨床療效. 方法 選取2014年1月—2015年6月來該院入住的糖尿病腎病患者186例,隨機分為對照組和觀察組,兩組成員均為93例.給予對照組單一貝那普利,給予觀察組貝那普利聯閤阨貝沙坦. 檢測尿微量白蛋白排洩率(UAER)、血尿素氮(BUN)、血肌酐(Scr)、收縮壓(SBP)、舒張壓(DBP)的變化,作為根據診斷標準,判定患者的有效率.結果 對照組和觀察組的UAER、SBP、DBP均降低,且觀察組降低的更加明顯.治療後比較,P<0.05,差異有統計學意義.BUN、Scr治療前後比較,P>0.05,差異無統計學意義.觀察組的不良反應較對照組少.對照組的總有效率為69.89%,觀察組的總有效率為90.32%,兩組數據相比,觀察組的有效率明顯優于對照組,統計學處理後差異有統計學意義(χ2=10.58,P<0.05). 結論 貝那普利聯閤阨貝沙坦治療糖尿病腎病時,能夠控製血糖和血壓、降低蛋白尿的排齣量,具有較好的治療療效,減少不良反應,改善瞭患者的生活質量. 因此值得廣汎應用.
목적 탐토패나보리연합액패사탄치료당뇨병신병적림상료효. 방법 선취2014년1월—2015년6월래해원입주적당뇨병신병환자186례,수궤분위대조조화관찰조,량조성원균위93례.급여대조조단일패나보리,급여관찰조패나보리연합액패사탄. 검측뇨미량백단백배설솔(UAER)、혈뇨소담(BUN)、혈기항(Scr)、수축압(SBP)、서장압(DBP)적변화,작위근거진단표준,판정환자적유효솔.결과 대조조화관찰조적UAER、SBP、DBP균강저,차관찰조강저적경가명현.치료후비교,P<0.05,차이유통계학의의.BUN、Scr치료전후비교,P>0.05,차이무통계학의의.관찰조적불량반응교대조조소.대조조적총유효솔위69.89%,관찰조적총유효솔위90.32%,량조수거상비,관찰조적유효솔명현우우대조조,통계학처리후차이유통계학의의(χ2=10.58,P<0.05). 결론 패나보리연합액패사탄치료당뇨병신병시,능구공제혈당화혈압、강저단백뇨적배출량,구유교호적치료료효,감소불량반응,개선료환자적생활질량. 인차치득엄범응용.
Objective To investigate the clinical efficacy of Benner Pury combined with irbesartan in the treatment of dia-betic nephropathy. Methods From January 2014 to June 2015, 186 cases of diabetic nephropathy patients were randomly di-vided into control group and observation group, two groups of 93 cases. The control group was given a single Benner Pury, the observation group was given irbesartan combined with Benner Pury. The changes of urinary albumin excretion rate (UAER), blood urea nitrogen (BUN), serum creatinine (Scr), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were determined. Results SBP, DBP and UAER in the control group and the observation group were lower, and the observa-tion group was more obvious. After treatment, P<0.05, with significant difference, had statistical significance. BUN, Scr be-fore and after treatment, there was no significant difference between P>0.05. The observation group of adverse reactions were less than the control group. In the control group the total efficiency is 69.89% in the observation group, the total effi-ciency was 90.32%, compared to the data of the two groups, the observation group efficiency is obviously superior to the control group, statistically difference is significant (χ2=10.58, P<0.05). Conclusion Benazepril combined with irbesartan in the treatment of diabetic nephropathy, to control blood glucose and blood pressure, reduce urinary protein excretion, with better efficacy, reduce the adverse reactions, and improve the quality of life of patients. Therefore, it is worthy of wide application.
